New Mastocytosis Drug Offers Hope for Rare Disease Patients

Researchers at the University of Basel have developed an artificial intelligence tool to more accurately measure the effectiveness of a new drug for mastocytosis, a rare disease characterized by an overabundance of mast cells. The AI quantitatively assesses the reduction of skin lesions associated with the condition, offering a more precise method of tracking treatment progress than visual assessment alone.

Mastocytosis is a diverse group of disorders resulting from the abnormal accumulation of mast cells in various tissues, including the skin, bone marrow, liver, spleen, gastrointestinal tract, and lymph nodes, according to DermNet NZ. The disease manifests in a range of symptoms, including skin lesions, itching, flushing, and, in severe cases, systemic complications. The World Health Organization in 2022 categorized three main types: cutaneous, systemic, and mast cell sarcomas.

The new drug, developed through research at the University of Basel, has shown promising results in reducing skin lesions. Traditionally, assessing treatment effectiveness has relied on subjective evaluations of these skin manifestations. The AI tool addresses this challenge by providing a quantitative measurement of improvement. Professor Karin Hartmann, an allergist and dermatologist at the University of Basel, has described the sensation experienced by patients as similar to the burning and itching from nettle contact.

Skin lesions in mastocytosis often appear as reddish-brown spots or patches, known as maculopapular lesions. The AI’s ability to accurately measure changes in these lesions is expected to accelerate the development of treatments for the disease. The methodology developed by the University of Basel team could potentially be adapted to assess treatment responses in other rare diseases characterized by visible skin manifestations, according to News Directory 3.

The research focuses on evaluating the impact of avapritinib, a recently developed drug showing promise in treating mastocytosis. Even as the study specifically centers on avapritinib, the AI-driven assessment method has broader implications for rare disease research.